Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 15/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591482 | 0.88 | IGF1R (0.40) | IGF1RCYP2E1 | |
| SCHEMBL4679278 | 0.81 | IGF1R (0.37) | IGF1RALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4683309 | 0.75 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3586932 | 0.72 | ALDH1A1 (0.37) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4682699 | 0.71 | GAA (0.38) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14066488 | 0.71 | PSEN1 (0.43) | IGF1R | |
| SCHEMBL4679791 | 0.70 | BLM (0.37) | IGF1R | |
| SCHEMBL4686151 | 0.69 | IGF1R (0.33) | IGF1RALDH1A1MAPT | |
| SCHEMBL6401628 | 0.69 | GAA (0.40) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4686158 | 0.68 | IGF1R (0.33) | IGF1RALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075984-A1 | DICARBONYLIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | LABORATORIOS SALVAT, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| EP-1976837-A1 | DICARBONYLIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Laboratorios SALVAT, S.A. (ES) | 2008-10-08 | — | — | EP | disclosed |
| EP-1437349-B9 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2008-09-10 | — | — | EP | disclosed |
| EP-1437349-B1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | S A L V A T LAB SA (ES) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007082910-A1 | DICARBONYLIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | LABORATORIOS SALVAT, S.A. (ES) | 2007-07-26 | — | — | WO | disclosed |
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-01-20 | — | — | US | disclosed |
| EP-1437349-A1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075984-A1 | DICARBONYLIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | AHR, DDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | IGF1R 2449/4885CYP2E1 194/4885MAOA 2470/4885 |
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | XDH, SCO2, HAX1 | IGF1R 798/4885CYP2E1 69/4885MAOA 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.